89bio ^{Priced, Nasdaq: ETNB}

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Our lead product candidate, BIO89-100, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, hepatocellular carcinoma and death. There are currently no approved products for the treatment of NASH. We believe BIO89-100 may be a differentiated FGF21 therapy based on its biological effects and tolerability profile, as well its potential for a longer dosing interval. We successfully completed a Phase 1a, first-in-human, single ascending dose clinical trial with 58 healthy volunteers, and results showed robust and durable biological effects. In July 2019, we initiated our proof of concept Phase 1b/2a clinical trial in patients with NASH or patients with NAFLD and a high risk of NASH and we expect to report topline data in the second half of 2020.